Conatus Pharmaceuticals News Releases https://ir.conatuspharma.com/ Conatus Pharmaceuticals News Releases en Conatus Pharmaceuticals Reports First Quarter 2019 Financial Results and Program Updates https://ir.conatuspharma.com/news-releases/news-release-details/conatus-pharmaceuticals-reports-first-quarter-2019-financial SAN DIEGO , May 02, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2019 , and provided updates on its development programs. Program Updates The company is currently conducting two double-blind, Thu, 02 May 2019 16:05:00 -0400 Conatus Pharmaceuticals News Releases 9771 Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis https://ir.conatuspharma.com/news-releases/news-release-details/conatus-pharmaceuticals-announces-publication-demonstrating SAN DIEGO , April 30, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced a new publication 1 in Hepatology Communications detailing results following seven-day treatment with emricasan, the company’s first-in-class pan-caspase inhibitor, in rats with advanced Tue, 30 Apr 2019 07:30:00 -0400 Conatus Pharmaceuticals News Releases 9766 Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension https://ir.conatuspharma.com/news-releases/news-release-details/conatus-late-breaker-oral-presentation-easl-meeting-details SAN DIEGO , April 15, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that the company’s late-breaker oral presentation at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria Mon, 15 Apr 2019 07:30:00 -0400 Conatus Pharmaceuticals News Releases 9751 Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference https://ir.conatuspharma.com/news-releases/news-release-details/conatus-pharmaceuticals-participate-hc-wainwright-global-life SAN DIEGO , April 02, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted an invitation to participate in the H.C. Wainwright Global Life Sciences Conference ( April 7-9 in London ). Conatus senior management will conduct a series of scheduled meetings with investment Tue, 02 Apr 2019 07:30:00 -0400 Conatus Pharmaceuticals News Releases 9701 Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis https://ir.conatuspharma.com/news-releases/news-release-details/conatus-announces-top-line-results-encore-nf-phase-2b-clinical Shortfall on Primary Endpoint Shifts Focus for Emricasan to Ongoing NASH Cirrhosis Trials SAN DIEGO , March 21, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed Thu, 21 Mar 2019 16:05:00 -0400 Conatus Pharmaceuticals News Releases 9686 Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension https://ir.conatuspharma.com/news-releases/news-release-details/conatus-late-breaker-oral-presentation-easl-meeting-detail SAN DIEGO , March 13, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the acceptance of an abstract for a late-breaker oral presentation at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the Liver (EASL) Wed, 13 Mar 2019 09:00:00 -0400 Conatus Pharmaceuticals News Releases 9681 Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates https://ir.conatuspharma.com/news-releases/news-release-details/conatus-pharmaceuticals-reports-2018-financial-results-and SAN DIEGO , March 08, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2018 , and provided updates on its development programs. Program Updates The company is conducting three double-blind, Fri, 08 Mar 2019 16:05:00 -0500 Conatus Pharmaceuticals News Releases 9661 Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results https://ir.conatuspharma.com/news-releases/news-release-details/conatus-pharmaceuticals-report-fourth-quarter-and-full-year-2018 SAN DIEGO , March 01, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2018 , after the market close on Friday, March 8, 2019 . Fri, 01 Mar 2019 07:30:00 -0500 Conatus Pharmaceuticals News Releases 9656 Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis https://ir.conatuspharma.com/news-releases/news-release-details/conatus-announces-completion-enrollment-encore-lf-phase-2b SAN DIEGO , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor. Tue, 12 Feb 2019 07:30:00 -0500 Conatus Pharmaceuticals News Releases 9646 Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials https://ir.conatuspharma.com/news-releases/news-release-details/conatus-pharmaceuticals-announces-publications-expanding SAN DIEGO , Jan. 28, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced publications expanding on previously reported results from three of the company’s completed Phase 2 clinical trials. Mitchell Schiffman , M.D., is the lead author on a new publication 1 in Mon, 28 Jan 2019 07:30:00 -0500 Conatus Pharmaceuticals News Releases 9596